Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getein BiotechSHSE:603387 +2.18%77 OCF Yield % is 9.23 as of Aug. 02, 2026, which is 63% above its 10-year median of 5.68. GuruFocus rates SHSE:603387 with a GF Score™ of 77/100 and a GF Value™ of ¥7.57 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 850 Medical Devices & Instruments companies, Getein Biotech ranks better than 83.76% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Getein Biotech's OCF Yield % or its related term are showing as below:
SHSE:603387'
s OCF Yield % Range Over the Past 10 Years
Min: 1.28 Med: 5.68 Max: 10.93
Current: 9.23
During the past 13 years, the highest OCF Yield % of Getein Biotech was 10.93%. The lowest was 1.28%. And the median was 5.68%.
SHSE:603387's OCF Yield % is ranked better than 83.76% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: 1.685
vs SHSE:603387: 9.23
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Getein Biotech OCF Yield % Related Terms
Getein Biotech OCF Yield % Historical Data
* Premium members only.
The historical data trend for Getein Biotech's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603387 vs ABT, SYK, MDT: OCF Yield % Comparison
For the Medical Devices subindustry, Getein Biotech's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getein Biotech OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Getein Biotech's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Getein Biotech (SHSE:603387) has a OCF Yield % of 9.23 as of Aug. 02, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Getein Biotech and its competitors. This is 63% above median its historical median of 5.68. Over the past decade, Getein Biotech's OCF Yield % has ranged from 1.28 to 10.93. According to the industry distribution chart, Getein Biotech ranks #138 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 16.2%.
Is Getein Biotech's OCF Yield % too high?
Getein Biotech's current OCF Yield % of 9.23 is 63% above median its 10-year median of 5.68. Over the past 10 years, this metric has ranged from a low of 1.28 to a high of 10.93. The Medical Devices & Instruments industry median OCF Yield % is 1.69. Getein Biotech's value of 9.23 is 447.8% above this industry median. Based on the distribution chart, Getein Biotech ranks #138 out of 850 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Getein Biotech has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getein Biotech's OCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getein Biotech ranks #138 out of 850 companies for OCF Yield %. This places Getein Biotech in the top 16% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 1.69. Getein Biotech's value of 9.23 is 447.8% above this benchmark. Historically, Getein Biotech's own OCF Yield % has ranged from 1.28 to 10.93 over the past decade. While the company's 10-year median is 5.68 vs. the industry median of 1.69, Getein Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.69, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getein Biotech's current OCF Yield % of 9.23 is 447.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Getein Biotech and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getein Biotech's current OCF Yield % is 9.23, which is 63% above median its own 10-year median of 5.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Getein Biotech (SHSE:603387) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥7.57, compared to a current price of ¥8.90 — trading 17.6% above its estimated fair value. The current OCF Yield % is 9.23, which is 63% above median its 10-year median of 5.68 and 447.8% above the Medical Devices & Instruments industry median of 1.69. Getein Biotech's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Getein Biotech (SHSE:603387), the current OCF Yield % is 9.23 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getein Biotech (SHSE:603387) Overvalued in 2026?
Based on GuruFocus' analysis, Getein Biotech stock appears to be overvalued.
The current stock price of ¥8.90 is trading 17.6% above its estimated GF Value™ of ¥7.57.
GuruFocus considers Getein Biotech to be Modestly Overvalued.
Key valuation signals for SHSE:603387:
OCF Yield %: 9.23 (63% above median its 10-year median of 5.68)
GF Value™: ¥7.57 vs. price of ¥8.90 (17.6% above fair value)
Industry Position: 447.8% above the Medical Devices & Instruments median (#138 of 850)
No single metric tells the full story. See the SHSE:603387 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
77GF Score
Get the complete analysis for SHSE:603387
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603387 has been successfully added to your 
